HUP0000658A2 - Szulfonamidszármazékok, eljárás előállításukra és gyógyszerként való alkalmazásuk - Google Patents
Szulfonamidszármazékok, eljárás előállításukra és gyógyszerként való alkalmazásukInfo
- Publication number
- HUP0000658A2 HUP0000658A2 HU0000658A HUP0000658A HUP0000658A2 HU P0000658 A2 HUP0000658 A2 HU P0000658A2 HU 0000658 A HU0000658 A HU 0000658A HU P0000658 A HUP0000658 A HU P0000658A HU P0000658 A2 HUP0000658 A2 HU P0000658A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- alkoxy
- alkyl
- hydroxy
- heterocyclic group
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
- -1 trifluoromethoxy- Chemical class 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 2
- 125000001589 carboacyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Pyrrole Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
A találmány központi idegrendszeri aktivitással rendelkező (I)általános képletű vegyületekre - amelyek képletében P fenil-, naftilcsoport, biciklusos heterociklusos csoport vagy 5-7tagú heterociklusos csoport; A egyes kötés, alkilén- vagy alkeniléncsoport; R1 halogénatom, adott esetben egy vagy több halogénatommalszubsztituált alkilcsoport, cikloalkil-, alkil-karbonil-, alkoxi-,trifluor-metoxi-, hidroxi-, hidroxi-alkil-, hidroxi-alkoxi-, alkoxi-alkoxi-, alkanoil-, nitro-, amino-, alkil-amino-, dialkil-amino-,ciano-, fenil-, naftilcsoport, biciklusos heterociklusos csoport vagy5-7 tagú heterociklusos csoport; n 0, 1, 2, 3, 4, 5 vagy 6; R2 hidrogénatom, alkil- vagy aril-alkil-csoport; R3 jelentése azonos R5 jelentésével, vagy R3 és R5 együtt -(CH2)2O- vagy -(CH2)3O- csoportot képez, vagy R3 és R2 együtt -(CH2)2- vagy -(CH2)3- csoportot képez; R4 -X(CH2)p-R6 csoport, ahol X egyes kötés, metiléncsoport, oxigénatom, imino- vagy alkil-Ncsoport, p 0, 1, 2, 3, 4, 5 vagy 6, és R6 adott esetben szubsztituált 5-7 tagú heterociklusos csoport, vagy -NR7R8 általános képletű csoport; R5 hidrogén-, halogénatom, alkil-, cikloalkil-, alkil-karbonil-,alkoxi-, hidroxi-, hidroxi-alkil-, hidroxi-alkoxi-, alkoxi-alkoxi-,alkanoil-, nitro-, trifluor-metil-, ciano- vagy arilcsoport - ésgyógyászatilag elfogadható sóikra, előállítási eljárásaikra, avegyületeket tartalmazó gyógyszerkészítményekre és a vegyületekközponti idegrendszeri rendellenességek kezelésére történőalkalmazására vonatkozik. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9626377.7A GB9626377D0 (en) | 1996-12-19 | 1996-12-19 | Novel compounds |
GBGB9700901.3A GB9700901D0 (en) | 1997-01-17 | 1997-01-17 | Novel compounds |
GBGB9722757.3A GB9722757D0 (en) | 1997-10-27 | 1997-10-27 | Novel compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0000658A2 true HUP0000658A2 (hu) | 2001-02-28 |
HUP0000658A3 HUP0000658A3 (en) | 2001-03-28 |
Family
ID=27268644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0000658A HUP0000658A3 (en) | 1996-12-19 | 1997-12-15 | Sulphonamide derivatives, process for their preparation, and their use as medicaments |
Country Status (31)
Country | Link |
---|---|
US (2) | US6423717B1 (hu) |
EP (1) | EP0946539B1 (hu) |
JP (1) | JP2001506646A (hu) |
KR (1) | KR20000069554A (hu) |
CN (1) | CN1246116A (hu) |
AP (1) | AP1277A (hu) |
AR (1) | AR010795A1 (hu) |
AT (1) | ATE247099T1 (hu) |
AU (1) | AU729056B2 (hu) |
BG (1) | BG103530A (hu) |
BR (1) | BR9713734A (hu) |
CA (1) | CA2275492A1 (hu) |
CZ (1) | CZ220399A3 (hu) |
DE (1) | DE69724142T2 (hu) |
DZ (1) | DZ2376A1 (hu) |
EA (1) | EA002351B1 (hu) |
ES (1) | ES2203831T3 (hu) |
HU (1) | HUP0000658A3 (hu) |
ID (1) | ID22821A (hu) |
IL (1) | IL130297A0 (hu) |
MA (1) | MA24426A1 (hu) |
NO (1) | NO993003D0 (hu) |
NZ (1) | NZ335970A (hu) |
OA (1) | OA11066A (hu) |
PE (1) | PE46899A1 (hu) |
PL (1) | PL334337A1 (hu) |
SK (1) | SK80899A3 (hu) |
TR (1) | TR199901361T2 (hu) |
TW (1) | TW418205B (hu) |
UY (1) | UY24819A1 (hu) |
WO (1) | WO1998027081A1 (hu) |
Families Citing this family (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
HUP0003073A3 (en) | 1997-07-11 | 2002-10-28 | Smithkline Beecham Plc | Benzenesulfonamide derivatives, process for producing them and their use as medicines |
ES2317688T3 (es) | 1998-01-29 | 2009-04-16 | Amgen Inc. | Moduladores ppar-gamma. |
GB9803411D0 (en) * | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
GB9810671D0 (en) * | 1998-05-18 | 1998-07-15 | Pfizer Ltd | Anti-pruritic agents |
GB9818916D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
GB9818914D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
GB9820113D0 (en) | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
GB9926302D0 (en) * | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
WO2001045694A1 (en) * | 1999-12-21 | 2001-06-28 | Smithkline Beecham Corporation | Urotensin-ii receptor antagonists |
SE9904723D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
SE0002754D0 (sv) * | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New pharmaceutical combination formulation and method of treatment with the combination |
SE0002739D0 (sv) * | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New use |
US6818639B2 (en) | 2000-07-21 | 2004-11-16 | Biovitrum Ab | Pharmaceutical combination formulation and method of treatment with the combination |
US6399617B1 (en) | 2000-07-21 | 2002-06-04 | Biovitrum Ab | Use |
US7071220B2 (en) | 2000-09-18 | 2006-07-04 | Toa Eiyo Ltd. | N-substituted benzothiophenesulfonamide derivatives |
CN1245400C (zh) * | 2000-09-18 | 2006-03-15 | 东亚荣养株式会社 | N-取代苯并噻唑磺胺衍生物 |
US7034029B2 (en) | 2000-11-02 | 2006-04-25 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
WO2002042293A1 (en) * | 2000-11-21 | 2002-05-30 | Smithkline Beecham P.L.C. | Isoquinoline derivatives useful in the treatment of cns disorders |
CA2432713C (en) | 2000-12-22 | 2009-10-27 | Ishihara Sangyo Kaisha, Ltd. | Aniline derivatives or salts thereof and cytokine production inhibitors containing the same |
WO2002088101A2 (en) * | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
AR033879A1 (es) | 2001-05-07 | 2004-01-07 | Smithkline Beecham Corp | Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto |
EP1387679A4 (en) * | 2001-05-07 | 2004-08-11 | Smithkline Beecham Corp | SULPHONAMIDES |
EP1399137A4 (en) * | 2001-05-07 | 2005-12-14 | Smithkline Beecham Corp | SULPHONAMIDES |
EP1385495A4 (en) * | 2001-05-07 | 2005-12-21 | Smithkline Beecham Corp | SULPHONAMIDES |
EP1385830A4 (en) * | 2001-05-07 | 2005-08-17 | Smithkline Beecham Corp | SULPHONAMIDES |
US6743796B2 (en) * | 2001-05-07 | 2004-06-01 | Wyeth | Piperazinyl-isatins |
GB0111186D0 (en) * | 2001-05-08 | 2001-06-27 | Smithkline Beecham Plc | Novel compounds |
KR100922486B1 (ko) * | 2001-05-11 | 2009-10-20 | 바이오비트럼 에이비(피유비엘) | 비만, 제 ⅱ 형 당뇨병 및 cns 장애의 치료를 위한신규한 아릴술폰아미드 화합물 |
MXPA03010232A (es) | 2001-05-11 | 2004-03-16 | Biovitrum Ab | Compuestos de arilsulfonamida, para el tratamiento de la obesidad, de la diabetes tipo ii y de trastornos del sistema nervioso central. |
US7718650B2 (en) | 2001-05-11 | 2010-05-18 | Biovitrum Ab | Aryl sulfonamide compounds for treating obesity |
WO2002098857A1 (en) | 2001-06-07 | 2002-12-12 | F. Hoffmann-La Roche Ag | New indole derivatives with 5-ht6 receptor affinity |
US7144883B2 (en) * | 2001-06-11 | 2006-12-05 | Biovitrum Ab | Bicyclic sulfonamide compounds |
MXPA03011638A (es) | 2001-06-15 | 2004-04-02 | Hoffmann La Roche | Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6. |
US6727264B1 (en) | 2001-07-05 | 2004-04-27 | Synaptic Pharmaceutical Corporation | Substituted anilinic piperidines as MCH selective antagonists |
JP2005527463A (ja) * | 2001-08-07 | 2005-09-15 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Cns疾患を治療するための5−ht6受容体アフィニティーを有する3−アリールスルホニル−7−ピペラジニル−インドール、−ベンゾフランおよび−ベンゾチオフェン |
PL373397A1 (en) * | 2001-08-10 | 2005-08-22 | F.Hoffmann-La Roche Ag | Arylsulfonyl derivatives with 5-ht6 receptor affinity |
JP4221294B2 (ja) | 2001-09-05 | 2009-02-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 摂食亢進剤および食欲不振症治療剤 |
SE0103644D0 (sv) * | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic isoquinoline compounds |
ATE429916T1 (de) * | 2001-11-09 | 2009-05-15 | Biovitrum Ab Publ | Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme |
RS44204A (en) | 2001-11-22 | 2007-06-04 | Biovitrum Ab., | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
RS44304A (en) | 2001-11-22 | 2007-06-04 | Biovitrum Ab., | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
JP2005516903A (ja) * | 2001-11-30 | 2005-06-09 | エフ.ホフマン−ラ ロシュ アーゲー | 喘息の処置におけるccr−3受容体拮抗物質として使用するためのピペラジン誘導体 |
AU2003203148A1 (en) * | 2002-02-05 | 2003-09-02 | High Point Pharmaceuticals, Llc | Novel aryl- and heteroarylpiperazines |
US20070270432A1 (en) * | 2002-02-05 | 2007-11-22 | James Hagan | Novel Method |
BR0307557A (pt) * | 2002-02-13 | 2005-01-04 | Glaxo Group Ltd | Derivados benzenosulfonamida como agentes antipsicóticos |
US20050085461A1 (en) * | 2002-02-13 | 2005-04-21 | Cooper David G. | Benzenesulfonamide derivatives |
DE60304695T2 (de) * | 2002-02-13 | 2006-09-21 | Glaxo Group Ltd., Greenford | 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo[d]azepin-derivate mit 5-hat-6-rezeptor affinität zur behandlung von erkrankungen des zentralnervensystems |
DK1497266T3 (da) | 2002-03-27 | 2008-10-06 | Glaxo Group Ltd | Quinolinderivater og deres anvendelse som 5HT6-ligander |
US20040142948A1 (en) * | 2002-05-07 | 2004-07-22 | Dashyant Dhanak | Sulfonamides |
MXPA04011254A (es) * | 2002-05-13 | 2005-01-25 | Hoffmann La Roche | Derivados de benzoxazina como moduladores de 5-hidroxitriptamina 6 (5-ht6) y usos de los mismos. |
EP1897876A3 (en) | 2002-06-20 | 2009-03-18 | Biovitrum AB (publ) | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
SG156524A1 (en) * | 2002-06-20 | 2009-11-26 | Biovitrum Ab Publ | New compounds useful for the treatment of obesity, type ii diabetes and cns disorders |
JP4754821B2 (ja) * | 2002-06-20 | 2011-08-24 | プロキシマゲン・リミテッド | 肥満症、ii型糖尿病およびcns障害の治療に有用な新規化合物 |
ES2274285T3 (es) | 2002-10-18 | 2007-05-16 | F. Hoffmann-La Roche Ag | 4-piperanzinilbencenosulfonilindoles con afinidad al receptor 5-ht6. |
WO2004043369A2 (en) * | 2002-11-06 | 2004-05-27 | Smithkline Beecham Corporation | Sulfonamides |
WO2004043368A2 (en) * | 2002-11-06 | 2004-05-27 | Smithkline Beecham Corporation | Sulfonamides |
ES2295816T3 (es) | 2003-01-14 | 2008-04-16 | Arena Pharmaceuticals, Inc. | Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia. |
US7153858B2 (en) | 2003-01-31 | 2006-12-26 | Epix Delaware, Inc. | Arylpiperazinyl compounds |
WO2004072087A2 (de) * | 2003-02-13 | 2004-08-26 | Lanxess Deutschland Gmbh | Metallkomplexe als lichtabsorbierende verbindungen in der informationsschicht von optischen datenträgern |
AU2004212985B2 (en) * | 2003-02-20 | 2010-10-14 | Encysive Pharmaceuticals Inc. | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists |
TWI289141B (en) | 2003-03-11 | 2007-11-01 | Hoffmann La Roche F. Ag. | Quinolinone derivatives and uses thereof |
US7262197B2 (en) * | 2003-03-31 | 2007-08-28 | Janssen Pharmaceutica, N.V | Phospholipase C inhibitors for use in treating inflammatory disorders |
US6946466B2 (en) * | 2003-04-10 | 2005-09-20 | Schering Ag | Aromatic sulfonamides as peroxynitrite-rearrangement catalysts |
US20040204422A1 (en) * | 2003-04-14 | 2004-10-14 | Abbott Gmbh & Co. Kg. | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds |
US8754238B2 (en) | 2003-07-22 | 2014-06-17 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
GB0320320D0 (en) * | 2003-08-29 | 2003-10-01 | Glaxo Group Ltd | Novel compounds |
US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
BRPI0417833A (pt) * | 2003-12-19 | 2007-04-17 | Biovitrum Ab | novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6 |
SE0303480D0 (sv) * | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
CA2575359A1 (en) * | 2004-07-28 | 2006-02-02 | Glaxo Group Limited | Piperazine derivatives useful for the treatment of gastrointestinal disorders |
CN101031338B (zh) * | 2004-09-30 | 2013-01-02 | 弗·哈夫曼-拉罗切有限公司 | 治疗认知障碍的组合物和方法 |
WO2006040176A1 (en) | 2004-10-14 | 2006-04-20 | Abbott Gmbh & Co. Kg | Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
AU2005293698B2 (en) | 2004-10-14 | 2011-12-15 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
WO2006062481A1 (en) * | 2004-12-09 | 2006-06-15 | Biovitrum Ab | New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders . |
EP1676841A1 (en) * | 2004-12-30 | 2006-07-05 | Esteve Laboratorios Dr. Esteve S.A. | Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments |
WO2006075808A1 (en) * | 2005-01-12 | 2006-07-20 | Inje University | Pharmaceutical composition comprising a p25/cdk5 inhibitor for preventing or treating a neurodegenerative disease |
EP2386554A1 (en) | 2005-07-04 | 2011-11-16 | High Point Pharmaceuticals, LLC | Compounds active at the histamine H3 receptor |
US7998981B2 (en) | 2005-08-12 | 2011-08-16 | Suven Life Sciences Limited | Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands |
US7923566B2 (en) | 2005-08-16 | 2011-04-12 | Suven Life Sciences Limited | Alternative process for the preparation of losartan |
US20100048713A1 (en) * | 2006-01-06 | 2010-02-25 | Aarhus Universitet | Compounds acting on the serotonin transporter |
AR060213A1 (es) | 2006-03-31 | 2008-06-04 | Glaxo Group Ltd | Compuesto de piperazinil - piridinil -bencensulfonamida , su uso para fabricar un medicamento proceso para la preparacion del mismo composicion farmaceutica que lo comprende y proceso para prepararla |
UY30295A1 (es) * | 2006-04-19 | 2007-11-30 | Abbott Gmbh & Amp | Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6 |
EP2074110A1 (en) | 2006-04-19 | 2009-07-01 | Abbott GmbH & Co. KG | Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor |
WO2007135111A1 (en) | 2006-05-23 | 2007-11-29 | High Point Pharmaceuticals, Llc | 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament |
EP2079732B9 (en) | 2006-05-29 | 2012-03-21 | High Point Pharmaceuticals, LLC | 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist |
CA2669117A1 (en) | 2006-10-26 | 2008-05-02 | Gary A. Flynn | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance |
ATE491685T1 (de) | 2007-01-08 | 2011-01-15 | Suven Life Sciences Ltd | 5-(heterocyclyl)alkyl-n- (arylsulfonyl)indolverbindungen und ihre verwendung als 5-ht6-liganden |
EP2118062A1 (en) | 2007-01-10 | 2009-11-18 | F. Hoffmann-Roche AG | Sulfonamide derivatives as chymase inhibitors |
CA2681034A1 (en) | 2007-03-23 | 2008-10-02 | Abbott Gmbh & Co. Kg | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
DK2155674T3 (da) | 2007-05-03 | 2011-09-26 | Suven Life Sciences Ltd | Aminoalkoxy-aryl-sulfonamidforbindelser og anvendelse heraf som 5-HT6-ligander |
EP2014656A3 (en) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
ES2359170T3 (es) * | 2007-07-19 | 2011-05-19 | Laboratorios Del Dr. Esteve S.A. | Compuestos tetrahidro-quinolín-sulfonamida sustituidos, su preparación y uso como medicamentos. |
AU2008315309B2 (en) | 2007-10-26 | 2011-06-09 | Suven Life Sciences Limited | Amino arylsulfonamide compounds and their use as 5-HT6 ligands |
PA8802201A1 (es) * | 2007-11-02 | 2009-06-23 | Abbott Gmbh & Co Kg | Compuestos de bencensulfonalida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 |
US9084742B2 (en) | 2007-12-12 | 2015-07-21 | Axovant Sciences Ltd. | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline |
US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
EP2288345B1 (en) | 2008-04-18 | 2015-06-10 | University College Dublin National University Of Ireland, Dublin | Psycho-pharmaceuticals |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
KR20110017432A (ko) * | 2008-06-11 | 2011-02-21 | 아이알엠 엘엘씨 | 말라리아의 치료에 유용한 화합물 및 조성물 |
CA2737282C (en) | 2008-09-17 | 2014-03-25 | Suven Life Sciences Limited | Aryl sulfonamide amine compounds and their use as 5-ht6 ligands |
WO2010032257A1 (en) | 2008-09-17 | 2010-03-25 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
UA100192C2 (en) | 2008-11-11 | 2012-11-26 | УАЙТ ЭлЭлСи | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands |
KR101073703B1 (ko) | 2009-04-07 | 2011-10-14 | 한국화학연구원 | 피페라진 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환의 예방 또는 치료용 약학적 조성물 |
SG175187A1 (en) | 2009-04-30 | 2011-11-28 | Abbott Gmbh & Co Kg | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
WO2010125136A1 (en) * | 2009-04-30 | 2010-11-04 | Abbott Gmbh & Co. Kg | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
US8343959B2 (en) | 2009-04-30 | 2013-01-01 | Abbott Gmbh & Co. Kg | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
EP2424844A1 (en) * | 2009-04-30 | 2012-03-07 | Abbott GmbH & Co. KG | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
EA022043B1 (ru) | 2010-01-05 | 2015-10-30 | Сувен Лайф Сайенсиз Лимитед | Сульфоновые соединения в качестве лигандов 5-htрецептора |
WO2012040279A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012059431A1 (en) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor |
WO2012059432A1 (en) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor |
ES2413911B1 (es) * | 2011-12-15 | 2014-05-14 | Universidad De Zaragoza | Agente inhibidor de la agregación del peptido beta amiloide. |
CN104220421A (zh) | 2012-03-20 | 2014-12-17 | 阿达梅德公司 | 用于治疗中枢神经系统疾病的苄胺的磺酰胺衍生物 |
CA2905993C (en) | 2013-03-14 | 2022-12-06 | Tolero Pharmaceuticals, Inc. | Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors |
SI3027613T1 (sl) | 2013-07-25 | 2018-10-30 | Uniwersytet Jagiellonski | Derivati pirolokvinolina kot 5-HT6 antagonisti, postopek priprave in uporabe le-teh |
US9840482B2 (en) | 2014-04-19 | 2017-12-12 | Sunshine Lake Pharma Co., Ltd. | Sulfonamide derivatives and pharmaceutical applications thereof |
CN105367472B (zh) * | 2014-08-12 | 2020-04-21 | 广东东阳光药业有限公司 | 吲哚啉类衍生物及其在药物上的应用 |
CN105367473B (zh) * | 2014-08-12 | 2020-02-11 | 广东东阳光药业有限公司 | 吲哚啉类衍生物及其在药物上的应用 |
NZ734220A (en) | 2015-01-06 | 2022-01-28 | Arena Pharm Inc | Methods of treating conditions related to the s1p1 receptor |
KR20180022792A (ko) | 2015-06-12 | 2018-03-06 | 엑소반트 사이언시즈 게엠베하 | 렘 수면 행동 장애의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴 우레아 유도체 |
MA42807A (fr) | 2015-06-22 | 2018-07-25 | Arena Pharm Inc | Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1 |
BR112018000728A2 (pt) | 2015-07-15 | 2018-09-04 | Axovant Sciences Gmbh | resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo |
CN108926565A (zh) * | 2017-05-26 | 2018-12-04 | 中国科学院上海生命科学研究院 | 五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用 |
WO2019180176A1 (en) | 2018-03-21 | 2019-09-26 | Spherium Biomed, S.L. | Composition for the treatment of schizophrenia and/or psychosis |
MX2021000977A (es) | 2018-07-26 | 2021-04-12 | Sumitomo Pharma Oncology Inc | Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos. |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE81861C (hu) | ||||
NZ193654A (en) * | 1979-05-16 | 1984-08-24 | Wuelfing Johann A | Naphthalene sulphonamido-alkyl-piperidines,pyrrolidines or piperazines and pharmaceutical compositions |
US4315014A (en) * | 1980-09-24 | 1982-02-09 | Warner-Lambert Company | Antibacterial amide compounds and pharmaceutical composition containing the same |
DE3276313D1 (en) * | 1981-09-24 | 1987-06-19 | Beecham Wuelfing Gmbh & Co Kg | Sulphonamides |
CN85106905A (zh) * | 1985-08-08 | 1987-02-04 | Fmc公司 | 含有1-芳基-δ2-1,2,4,-三唑啉-5-酮类的除草剂及其制备方法 |
AU5175490A (en) * | 1989-02-27 | 1990-09-26 | Du Pont Merck Pharmaceutical Company, The | Novel sulfonamides as radiosensitizers |
JPH04330057A (ja) * | 1991-05-01 | 1992-11-18 | Hiroyoshi Hidaka | アニリンアリールスルホン酸アミド類及び薬剤として許容され得るその酸付加塩 |
GB9119932D0 (en) * | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
DE4206531A1 (de) * | 1992-03-02 | 1993-09-09 | Bayer Ag | N-aryl-stickstoffheterocyclen |
DE4303376A1 (de) * | 1993-02-05 | 1994-08-11 | Bayer Ag | Substituierte Triazolinone |
JP3328936B2 (ja) * | 1993-09-03 | 2002-09-30 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 5ht1dレセプター拮抗薬用インドールおよびインドリン誘導体 |
WO1995011243A1 (en) * | 1993-10-19 | 1995-04-27 | Smithkline Beecham Plc | Benzanilide derivatives as 5ht-1d receptor antagonists |
WO1995015954A1 (en) * | 1993-12-07 | 1995-06-15 | Smithkline Beecham Plc | Heterocyclic biphenylylamides useful as 5ht1d antagonists |
WO1995032967A1 (en) * | 1994-05-28 | 1995-12-07 | Smithkline Beecham Plc | Amide derivatives having 5ht1d-antagonist activity |
US5939451A (en) | 1996-06-28 | 1999-08-17 | Hoffmann-La Roche Inc. | Use of sulfonamides |
DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
-
1997
- 1997-12-07 DZ DZ970226A patent/DZ2376A1/xx active
- 1997-12-15 ES ES97954929T patent/ES2203831T3/es not_active Expired - Lifetime
- 1997-12-15 PL PL97334337A patent/PL334337A1/xx unknown
- 1997-12-15 TR TR1999/01361T patent/TR199901361T2/xx unknown
- 1997-12-15 CN CN97181816A patent/CN1246116A/zh active Pending
- 1997-12-15 ID IDW990546A patent/ID22821A/id unknown
- 1997-12-15 EP EP97954929A patent/EP0946539B1/en not_active Expired - Lifetime
- 1997-12-15 HU HU0000658A patent/HUP0000658A3/hu unknown
- 1997-12-15 CA CA002275492A patent/CA2275492A1/en not_active Abandoned
- 1997-12-15 AT AT97954929T patent/ATE247099T1/de not_active IP Right Cessation
- 1997-12-15 IL IL13029797A patent/IL130297A0/xx unknown
- 1997-12-15 KR KR1019997005497A patent/KR20000069554A/ko not_active Application Discontinuation
- 1997-12-15 DE DE69724142T patent/DE69724142T2/de not_active Expired - Fee Related
- 1997-12-15 AU AU60904/98A patent/AU729056B2/en not_active Ceased
- 1997-12-15 BR BR9713734-0A patent/BR9713734A/pt not_active IP Right Cessation
- 1997-12-15 WO PCT/EP1997/007159 patent/WO1998027081A1/en not_active Application Discontinuation
- 1997-12-15 NZ NZ335970A patent/NZ335970A/en unknown
- 1997-12-15 AP APAP/P/1999/001556A patent/AP1277A/en active
- 1997-12-15 CZ CZ992203A patent/CZ220399A3/cs unknown
- 1997-12-15 EA EA199900561A patent/EA002351B1/ru not_active IP Right Cessation
- 1997-12-15 JP JP52734798A patent/JP2001506646A/ja not_active Ceased
- 1997-12-15 SK SK808-99A patent/SK80899A3/sk unknown
- 1997-12-17 PE PE1997001126A patent/PE46899A1/es not_active Application Discontinuation
- 1997-12-17 AR ARP970105951A patent/AR010795A1/es not_active Application Discontinuation
- 1997-12-17 MA MA24902A patent/MA24426A1/fr unknown
- 1997-12-18 TW TW086119136A patent/TW418205B/zh not_active IP Right Cessation
- 1997-12-18 UY UY24819A patent/UY24819A1/es not_active Application Discontinuation
-
1999
- 1999-06-18 NO NO993003A patent/NO993003D0/no not_active Application Discontinuation
- 1999-06-18 OA OA9900133A patent/OA11066A/en unknown
- 1999-06-25 BG BG103530A patent/BG103530A/bg unknown
-
2000
- 2000-08-21 US US09/643,200 patent/US6423717B1/en not_active Expired - Fee Related
-
2002
- 2002-05-29 US US10/157,258 patent/US6599904B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0000658A2 (hu) | Szulfonamidszármazékok, eljárás előállításukra és gyógyszerként való alkalmazásuk | |
HUP0003073A2 (hu) | Benzolszulfonamid-származékok, eljárás előállításukra és gyógyszerként való alkalmazásuk | |
HUP0300618A2 (hu) | Adamantánszármazékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
HUP9901820A2 (hu) | 4-Amino-pirimidin-származékok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra | |
HUP0002830A2 (hu) | Indol- és 2,3-dihidroindol-származékok, előállításuk és gyógyászati alkalmazásuk | |
HUP9901273A2 (hu) | Gyógyászatban alkalmazható aza-bicikloalkil-karbamát-származékok | |
HUP0004422A2 (hu) | 2-Aril-8-oxohidropurin-származékok, eljárás előállításukra, ilyen vegyületeket tartalmazó gyógyászati készítmények | |
UA66825C2 (uk) | Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності | |
HUP0004628A1 (hu) | Kamptotecinek új tetraciklusos analógjai, eljárás előállításukra, és ilyen vegyületeket tartalmazó gyógyászati készítmények | |
ES2164920T3 (es) | Nuevos derivados heterociclicos y uso medicinal de los mismos. | |
HUP0301069A2 (hu) | Új biaril-karboxamidok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
ES2169472T3 (es) | Analogos de benzamida, utiles como inhibidores de la enzima de reparacion del dna denominada parp (adp-ribosiltransferasa, adprt). | |
HUP0301508A2 (hu) | Antivirális hatású aza-indol-származékok és ezeket tartalmazó gyógyszerkészítmények, valamint intermedierek | |
HUP0001802A2 (hu) | Pirazin-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
HUP0400554A2 (hu) | Tetrahidropiridin-származékok, előállításuk és felhasználásuk sejtburjánzás-inhibitorként | |
HUP9902148A2 (hu) | Új 2,3-diszubsztituált-4(3H)-kinazolinonok | |
ATE25682T1 (de) | Indol-3-carboxamid-derivate. | |
AU6292280A (en) | Morpholine derivatives | |
NO990433L (no) | Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet | |
AU3060197A (en) | Aryl substituted cyclic amines as selective dopamine d3 ligands | |
HUP0001865A2 (hu) | Amino-pirimidin-származékok, alkalmazásuk, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
HUP0100558A2 (hu) | S-Oxid- és S,S-dioxid-tetrahidrotiopirán-fenil-oxazolidinon-származékok, e vegyületek alkalmazása gyógyászati készítmények előállítására, valamint eljárás e vegyületek gátló hatásának meghatározására humán-monoamin-oxidázzal szemben | |
HUP0003624A2 (hu) | 1,2,3,4-Tetrahidro-benzofuro[3,2-c]piridin-származékok, az ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
NO20015381L (no) | Cyklotiokarbamatderivater som progesteronreseptormodulatorer | |
ATE66673T1 (de) | 2-pyrrolidonderivate, verfahren zur herstellung, pharmazeutische zusammensetzungen und anwendung. |